公开(公告)号：US20200347020A1

公开(公告)日：2020-11-05

申请号：US16935565

申请日：2020-07-22

Applicant: Merck Sharp & Dohme Corp.

Inventor： Gregory L. Adams ,  Jason M. Cox ,  John S. Debenham ,  Scott Edmondson ,  Eric J. Gilbert ,  Yan Guo ,  Yu Jiang ,  Hubert Josien ,  Hyunjin M. Kim ,  Ping Lan ,  Shouwu Miao ,  Christopher W. Plummer ,  Murali Rajagopalan ,  Unmesh Shah ,  Zhongxiang Sun ,  Quang T. Truong ,  Feroze Ujjainwalla ,  Francisco Velazquez ,  Srikanth Venkatraman ,  Takao Suzuki ,  Nengxue Wang

IPC: C07D217/04 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D401/06 ,  C07D417/04 ,  A61K31/4725 ,  C07D417/06 ,  C07D217/22 ,  A61K45/06 ,  A61K31/472 ,  A61K9/48 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P29/00

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

公开(公告)号：US20190161448A1

公开(公告)日：2019-05-30

申请号：US16096710

申请日：2017-05-19

Applicant: Merck Sharp & Dohme Corp.

Inventor： Gregory L. Adams ,  Jason M. Cox ,  John S. Debenham ,  Scott Edmondson ,  Eric J. Gilbert ,  Yan Guo ,  Yu Jiang ,  Hubert Josien ,  Hyunjin M. Kim ,  Ping Lan ,  Shouwu Miao ,  Christopher W. Plummer ,  Murali Rajagopalan ,  Unmesh Shah ,  Zhongxiang Sun ,  Quang T. Truong ,  Feroze Ujjainwalla ,  Francisco Velazquez ,  Srikanth Venkatraman ,  Takao Suzuki ,  Nengxue Wang

IPC: C07D217/04 ,  C07D401/12 ,  C07D401/04 ,  C07D401/06 ,  C07D417/04 ,  C07D417/14 ,  C07D417/12 ,  C07D413/04 ,  A61P3/10 ,  A61P3/06 ,  A61P3/04 ,  A61P29/00

Abstract: The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

公开(公告)号：US11161819B2

公开(公告)日：2021-11-02

申请号：US16935565

申请日：2020-07-22

Applicant: Merck Sharp & Dohme Corp.

Inventor： Gregory L. Adams ,  Jason M. Cox ,  John S. Debenham ,  Scott Edmondson ,  Eric J. Gilbert ,  Yan Guo ,  Yu Jiang ,  Hubert Josien ,  Hyunjin M. Kim ,  Ping Lan ,  Shouwu Miao ,  Christopher W. Plummer ,  Murali Rajagopalan ,  Unmesh Shah ,  Zhongxiang Sun ,  Quang T. Truong ,  Feroze Ujjainwalla ,  Francisco Velazquez ,  Srikanth Venkatraman ,  Takao Suzuki ,  Nengxue Wang

IPC: C07D217/04 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D401/06 ,  C07D417/04 ,  A61K31/4725 ,  C07D417/06 ,  C07D217/22 ,  A61K45/06 ,  A61K31/472 ,  A61K9/48 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P29/00

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

公开(公告)号：US20190269679A1

公开(公告)日：2019-09-05

申请号：US16462344

申请日：2017-12-11

Applicant: Merck Sharp & Dohme Corp.

Inventor： John S. Debenham ,  Jason M. Cox ,  Ping Lan ,  Zhongxiang Sun ,  Zhe Feng ,  Chunrui Sun ,  Michael W. Seganish ,  Zhong Lai ,  Cheng Zhu ,  Thomas Bara ,  Murali Rajagopalan ,  Qun Dang ,  Hyunjin M. Kim ,  Bin Hu ,  Jinglai Hao

IPC: A61K31/497 ,  A61K31/4439 ,  A61K31/42 ,  A61K31/444 ,  C07D417/14 ,  C07D413/04 ,  C07D413/14 ,  C07D231/20

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

公开(公告)号：US08987195B2

公开(公告)日：2015-03-24

申请号：US13960343

申请日：2013-08-06

Applicant: Merck Sharp & Dohme Corp. ,  Merck Canada Inc.

Inventor： Thomas Bara ,  Sathesh Bhat ,  Dipshikha Biswas ,  Linda Brockunier ,  Duane A. Burnett ,  Samuel Chackalamannil ,  Mariappan V. Chelliah ,  Austin Chen ,  Martin Clasby ,  Vince J. Colandrea ,  Zhuyan Guo ,  Yongxin Han ,  Charles Jayne ,  Hubert Josien ,  Karen Marcantonio ,  Shouwu Miao ,  Santhosh Neelamkavil ,  Patrick Pinto ,  Murali Rajagopalan ,  Unmesh Shah ,  Francisco Velazquez ,  Srikanth Venkatraman ,  Yan Xia

IPC: A61K38/00 ,  C07K5/08 ,  A61K38/06 ,  A61K45/06 ,  C07D491/22 ,  C07D419/00

CPC classification number: C07K5/08 ,  A61K38/06 ,  A61K45/06 ,  C07D419/00 ,  C07D491/22

Abstract: The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

Abstract translation: 本发明涉及含有螺环状的丙型肝炎病毒（HCV）NS3蛋白酶抑制剂，这些化合物的用途，以及这些化合物的合成。